Basilea Pharmaceutica Logo

About Basilea Pharmaceutica

Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the company provides Zevtera, an antibiotic for the treatment of pneumonia, as well as develop for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin, and skin structure infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.